{"filing":{"accession_number":"0001193125-26-265934","cik":"0001652130","ticker":"NTLA","company_name":"Intellia Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"ntla-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526265934/ntla-20260609.htm"},"events":[{"id":5670,"run_id":4971,"accession_number":"0001193125-26-265934","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Intellia's Annual Meeting held on June 9, 2026. The filing presents voting results for three proposals: election of three class I directors (Muna Bhanji, Brian Goff, and Jesse Goodman), ratification of Deloitte \u0026 Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.","company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5921,"accession_number":"0001193125-26-265934","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Intellia's Annual Meeting held on June 9, 2026. The filing presents voting results for three proposals: election of three class I directors (Muna Bhanji, Brian Goff, and Jesse Goodman), ratification of Deloitte \u0026 Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:38:06.217694+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5921,"accession_number":"0001193125-26-265934","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Intellia's Annual Meeting held on June 9, 2026. The filing presents voting results for three proposals: election of three class I directors (Muna Bhanji, Brian Goff, and Jesse Goodman), ratification of Deloitte \u0026 Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:38:06.217694+00:00","company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","filing_date":"2026-06-10"}]}